# Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies

> **NCT04033159** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dynacure** · enrollment: 14 (actual)

## Conditions studied

- Centronuclear Myopathy

## Interventions

- **DRUG:** DYN101

## Key facts

- **NCT ID:** NCT04033159
- **Lead sponsor:** Dynacure
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-09
- **Primary completion:** 2022-06-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Based on tolerability findings at the low dose level thus far, continuation of dosing or even dose escalation is not possible.
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033159, "Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04033159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*